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The objective of the studywas to describe the subcutaneous interstitial fluid (ISF) pharmacokinetics of fluconazole in critically ill pa-
tientswith sepsis. This prospective observational studywas conducted at two tertiary intensive care units inAustralia. Serial flucona-
zole concentrationsweremeasured over 24 h in plasma and subcutaneous ISF usingmicrodialysis. The concentrations in plasma and
microdialysateweremeasured using a validated high-performance liquid chromatography systemwith electrospraymass spectrome-
ter detectormethod.Noncompartmental pharmacokinetic analysis was performed. Twelve critically ill patientswith sepsiswere en-
rolled. Themean in vivofluconazole recovery rates standard deviation (SD) formicrodialysis were 51.4% 16.1%with amean
(SD) fluconazole ISF penetration ratio of 0.52 0.30 (coefficient of variation, 58%). Themedian free plasma area under the concen-
tration-time curve from0 to 24 h (AUC0–24) was significantly higher than themedian ISFAUC0–24 (340.4 versus 141.1mg · h/liter;P
0.004). Therewas no statistical difference inmedian fluconazole ISF penetration between patients receiving andnot receiving vasopres-
sors (median, 0.28 versus 0.78;P 0.106). Bothminimumand themaximumconcentrations of drug in serum (Cmax andCmin) showed
a significant correlationwith the fluconazole plasma exposure (Cmax,R
2 0.86,P< 0.0001;Cmin,R
2 0.75,P< 0.001).Our data sug-
gest that fluconazolewas distributed variably, but incompletely, fromplasma into subcutaneous interstitial fluid in this cohort of criti-
cally ill patientswith sepsis. Given the variability of fluconazole interstitial fluid exposures and lack of clinically identifiable factors by
which to recognize patientswith reduced distribution/exposure, we suggest higher than standard doses to ensure that drug exposure is
adequate at the site of infection.
Infections and related sepsis are among the most important rea-sons for admission to intensive care units (ICUs). Candida sp.
infections are responsible for up to 30% and 38% of fungal sepsis
and septic shock episodes, respectively (1–4), and currently are the
third leading cause of infections in ICUs globally (5). The attrib-
utable mortality associated with candidiasis in ICU patients is es-
timated to be 28.3% (6).
Most Candida infections are extravascular in origin, with in-
terstitial fluid (ISF) of tissues and other body fluids representing
the actual target site for antifungal therapy to treat the vast major-
ity of Candida infections (7–9). While antibacterial treatment fail-
ures have been attributed to impaired target site penetration in
critically ill patients with sepsis and shock (9, 10), data on antifun-
gals are limited. However, it is highly likely that successful treat-
ment with antifungal agents relies on the achievement of adequate
concentrations at the site of infection, i.e., the ISF.
Fluconazole is a frequently used triazole antifungal agent in
ICUs. In addition to delay in initiating fluconazole therapy, inad-
equate fluconazole dosing is an independent predictor of mortal-
ity in ICU patients with Candida infections (11). Given increasing
evidence on the fluconazole exposure-response relationship (12–
15), knowledge of plasma and ISF fluconazole concentrations is
important to optimize exposure and hence response to flucona-
zole treatment in this cohort of critically ill patients.
In the present study, we investigated the pharmacokinetic (PK)
profile of fluconazole in plasma and subcutaneous (SC) ISF in
ICU patients with sepsis.
MATERIALS AND METHODS
This prospective observational study was conducted at two tertiary ICUs
in Australia between May 2012 and January 2014. The study protocol was
approved by the respective local human ethics committees (2012039 and
HREC/13/QRBW/75). Prior informed written consent was obtained from
either the patient or a substitute decision maker for the patient.
Study subjects. All ICU patients were screened, and eligible patients
were identified for participation in the study. Patients were eligible for
inclusion if the following criteria were met: at least 18 years old, admitted
to the ICU, presence of sepsis, arterial line in situ or planned insertion,
indwelling urinary catheter in situ or planned insertion, ability to obtain
prior informed consent from the patient or person responsible, and pre-
scription of intravenous fluconazole. Sepsis was defined as the presence of
a suspected or confirmed infection and two or more systemic inflamma-
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tory response syndrome criteria documented in the previous 24 h: a core
temperature of36.0°C or38.0°C; a heart rate of90 beats/minute; a
respiratory rate of20 breaths/minute, partial pressure of carbon dioxide
in the arterial blood (PaCO2) of 32 mm Hg, or the patient being me-
chanically ventilated for an acute process; and a white cell count (WCC) of
12.0 109 or4.0 109/liter or10% immature bands (16). Patients
who met one or both of the following criteria were excluded: (i) known or
suspected allergy to triazole antifungal agents or penicillins and (ii) preg-
nancy.
Drug administration. Fluconazole initiation and dose were at the dis-
cretion of the treating physician based on the clinical requirements.
Microdialysis procedure tomeasure ISF concentrations and in vivo
calibration. Microdialysis was used to measure the free (or unbound)
fluconazole concentration in subcutaneous-tissue ISF. The principles and
details of microdialysis have been described previously (17). In this study,
a microdialysis probe (CMA 60; Microdialysis AB, Stockholm, Sweden)
with a molecular-mass cutoff of 20 kDa, an outer diameter of 0.6 mm, and
a membrane length of 30 mm was aseptically placed in the subcutaneous
tissue of the upper arms of the patients following the local injection of
0.5% lidocaine solution (1.5 ml). The probe was then perfused with
flucloxacillin (10 mg/liter; internal standard, perfusate) in 0.9% sodium
chloride at a flow rate of 1.5 l/min. Flucloxacillin was chosen as the
internal standard for analytical purposes. The perfusion was initiated at
least 60 min prior to the sampling time to establish equilibrium. After
commencement of the fluconazole infusion, microdialysis samples were
collected (the sampling frequency is described below). The in vivo recov-
ery of fluconazole in the microdialysate was interpolated from the loss of
the internal standard (flucloxacillin) across the microdialysis membrane
into the subcutaneous ISF (18–22) using the following equation: percent
in vivo fluconazole recovery 100 (Cinmean Cout/Cin), where Cin is
flucloxacillin at 10 mg/liter (perfusate) and Cout is the measured flucloxa-
cillin concentration in the microvial (microdialysate).
Sample collection and processing. Arterial-blood samples were col-
lected during one dosing interval from an indwelling arterial line just
before commencing the fluconazole infusion (0 h) and at 0.5, 1, 2, 3, 4, 5,
6, 8, 12, and 24 h after commencement. Microdialysate samples were
collected at 30-min intervals between 0 and 6 h, hourly between 6 and 12
h, and then at 24 h. A 24-h urine sample was collected to measure creati-
nine clearance. Blood samples were centrifuged at 2,000  g for 10 min,
and plasma was collected. The plasma and microdialysate samples were
stored at80°C until analysis. Sample transport was carried out by using
dry ice and adhering to cold-chain procedures.
Data collection. Demographic and clinical data were collected, in-
cluding age, gender, height, weight, admission diagnosis, acute physiolog-
ical and chronic health evaluation (APACHE) II score, sequential organ
failure assessment (SOFA) score, receipt of mechanical ventilation, vaso-
active treatment, and response to fluconazole therapy (defined as cessa-
tion of fluconazole therapy without antifungal recommencement within
14 days).
Sample analysis. Plasma fluconazole concentrations and microdialy-
sate fluconazole and flucloxacillin concentrations were analyzed with a
high-performance liquid chromatography (HPLC) system with electros-
pray mass spectrometer detector (Applied Biosystems [Foster City, CA,
USA] API2000; Shimadzu [Kyoto, Japan] HPLC). Briefly, for plasma
samples, the method was as follows. Plasma (300l) was mixed with 50l
internal standard (voriconazole; 1 mg/liter) and precipitated with 150 l
of 10% trichloroacetic acid. The samples were centrifuged at 12,000  g
for 6 min at 4°C after being thoroughly vortexed for 30 s. The analytes
were separated through an Agilent Zorbax Eclipse XDB-c18 (2.1 by 150
mm; 3.5-m particle size) by gradient elution using water containing
0.1% formic acid and methanol containing 0.1% formic acid with a total
flow rate of 0.3 ml/min and detected by an electrospray positive-ioniza-
tion mode of tandem mass spectrometry. The mass-to-charge ratios (m/z)
in multiple-reaction monitoring were 307.3/127.0 for fluconazole and
349.9/224.0 for the internal standard. Microdialysate samples (10l) were
assayed directly without any sample preparation under the same condi-
tions used for the plasma samples. The calibration curve was linear over
the concentration range of 0.1 to 20 mg/liter for both plasma and micro-
dialysate samples. The intra- and interday coefficients of variation were
validated to be within 10% at low, medium, and high concentrations of
the calibration range. Assays were validated and conducted using criteria
from the U.S. Food and Drug Administration guidance on bioanalysis
(23).
PK analysis. Plasma and ISF PK parameters were estimated using
noncompartmental methods. The apparent terminal elimination rate
constant (kel) was determined from log-linear least-squares regression.
The minimum and maximum concentrations of drug in serum for the
dosing period (Cmin and Cmax) were the observed values. The half-life
(t1/2) was calculated as ln (2)/kel. The area under the plasma concentra-
tion-time curve from 0 to 24 h (AUC0 –24) was calculated using the linear
trapezoidal approximation. The area under the plasma concentration-
time curve from time zero to infinity (AUC0 –) was calculated by the
log-linear trapezoidal rule until the time of the last quantifiable plasma
concentration and then extrapolated to infinity by using the quotient of
the last measurable concentration to kel. Clearance (CL) was calculated
using the following formula: dose/AUC0 –. Protein binding of flucona-
zole was assumed to be 12% to determine free AUC0 –24 (fAUC0 –24) (24).
An fAUC0 –24/MIC ratio of100 was chosen as the target PK/pharmaco-
dynamic (PD) index associated with efficacy based on the EUCAST guide-
lines (25). The current EUCAST MIC breakpoints for fluconazole are as
follows: susceptible,2 mg/liter, and resistant,4 mg/liter. The current
CLSI MIC breakpoints are as follows: susceptible,2 mg/liter; susceptible
dose dependent, 4 mg/liter; and resistant,8 mg/liter. These breakpoints
apply to Candida albicans, Candida tropicalis, and Candida parapsilosis.
The estimated concentrations from microdialysis samples were cor-
rected, using the in vivo recovery calculated for fluconazole, prior to
pharmacokinetic analyses with the following equation: CISF  100 
(Cmicrodialysate/percent recovery in vivo), where CISF is the drug con-
centration in ISF and Cmicrodialysate is fluconazole concentration in the
microdialysate. ISF penetration ratios were calculated using the
AUC0 –24 for subcutaneous ISF concentrations and the fAUC0 –24 in
plasma (fAUC0 –24 plasma) as follows: ISF penetration ratio  AUCISF/
fAUC0 –24 plasma. A two-sided t test was used to compare the means of
concentrations in plasma and subcutaneous ISF and PK parameters.
The Mann-Whitney U test was used to compare the ISF penetration
between patients receiving and not receiving vasopressors. All analyses
were done using GraphPad Prism 5.03 for Windows (GraphPad Soft-
ware, San Diego, CA, USA).
RESULTS
Twelve patients were included in this study; six were female. All
patients were treated with 400 mg fluconazole (5.1 mg/kg of body
weight) administered once daily as an intravenous infusion over
60 min. All sampling occurred between days 3 and 5 after initia-
tion of fluconazole treatment. Seven (58.3%) patients received
fluconazole for the directed treatment—six (50%) patients for
intra-abdominal sepsis and one (8.3%) patient for lower respira-
tory tract infection. Three (25%) patients received empirical flu-
conazole for intra-abdominal sepsis, one (8.3%) patient received
empirical fluconazole for lower respiratory tract infections, and
one (8.3%) patient received fluconazole to treat C. albicans in a
submandibular abscess. An overview of the patient characteristics
is shown in Table 1.
Microbiology. Abdominal fluid was positive for C. albicans in
five patients and for Candida glabrata in one patient. Fluconazole
was changed to caspofungin in the last patient after identification
to the species level. Lower respiratory tract secretions were posi-
tive for C. albicans in one patient, and in one patient, the subman-
dibular abscess aspirate was positive forC. albicans. No otherCan-
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dida spp. were isolated in this patient cohort. The MIC values were
reported for only two patients (0.25 and 0.6 mg/liter), both of
which were below EUCAST and CLSI breakpoints for fluconazole.
Microdialysis. The mean in vivo fluconazole recovery rate for
microdialysis	 standard deviation (SD) was 51.4%	 16.1%. The
fluconazole ISF penetration was 0.52	 0.30 (coefficient of varia-
tion, 58%). The median (interquartile range [IQR]) fluconazole
ISF penetrations in patients receiving and not receiving vasopres-
sors were 0.28 (0.17 to 0.57) and 0.70 (0.48 to 0.94), respectively
(P 0.106). The ISF PK parameters are presented in Table 2.
Fluconazole PK. The concentration-time profile of flucona-
zole in plasma and ISF of subcutaneous soft tissue in critically ill
patients with sepsis is shown in Fig. 1. The free median plasma
AUC0 –24 was significantly higher than the median ISF AUC0 –24
(340.4 versus 141.1 mg · h/liter; P 0.004) (Fig. 2). Both Cmax and




Of the patients with Candida sp. isolates, those that responded to
treatment did not seem to have a fluconazole exposure different
from that of the patients who did not respond to the treatment; the
respective median (IQR) plasma exposures were 366 mg · h/liter
(257.4 to 485.7 mg · h/liter) and 454 mg · h/liter (391.9 to 516.1 mg
· h/liter), and the respective median (IQR) ISF exposures were 96.6
mg · h/liter (65.2 to 179.4 mg · h/liter) and 352.1 mg · h/liter (254.6
to 449.6 mg · h/liter).
PK/PD. Fluconazole PK/PD target attainment in both plasma
and ISF at EUCAST and CLSI breakpoints for C. albicans is shown
in Fig. 3. Both patients with reported MICs in this cohort attained
the PK/PD target (fAUC0 –24/MIC 100) in both plasma and ISF.
However, only one patient responded to the treatment as defined
above.
DISCUSSION
Our data suggest that fluconazole was distributed incompletely
from plasma into subcutaneous ISF in this cohort of critically ill
patients with sepsis, with a mean penetration ratio	 SD of 0.52	
0.30. Peak concentrations in ISF were reached at 3.8 h compared
to 1.4 h in plasma, suggesting delayed distribution into subcuta-
neous ISF. The variability in the observed fluconazole ISF pene-
tration among patients was high. This was evident from the coef-
ficient of variation (58%) observed among the patients. A large
proportion of patients in the cohort would have achieved an
fAUC0 –24/MIC of 100 in plasma at EUCAST and CLSI break-
points (Fig. 3). However, a majority of the patients would require
higher doses in order to achieve an fAUC0 –24/MIC of100 in ISF
(Fig. 3).
Sepsis- and septic-shock-related hemodynamic changes lead to
tissue hypoperfusion, which results in alterations in antimicrobial
pharmacokinetics (9, 26). During the initial stages of sepsis-re-
lated blood flow changes, hypoperfusion of vital organs occurs,




Age (yr) 53 (43–67)
Wt (kg) 75 (70–87)
Height (m) 1.7 (1.6–1.8)
CrCLmeasured (ml/min) 117.2 (74.0–143.3)
APACHE II score 18 (17.7–20.5)
SOFA score 3.5 (3.0–6.5)
Invasive ventilation [n (%)] 9 (75)
Vasopressor/inotropic support [n (%)] 5 (42)
a CrCLmeasured, measured creatinine clearance using 24-h urine collected on the
sampling day. APACHE and SOFA scores were calculated using the data obtained over
the preceding 24 h in relation to the sampling day. Vasopressor/inotropic support was
defined as the patient having received one of the following to maintain clinician-
targeted mean arterial pressure: noradrenaline, adrenaline, dopamine, vasopressin, and
dobutamine.





Cmax (mg/liter) 20.3 (17.2–26.4) 9.8 (6.3–16.0)
Tmax (h) 1.4 (1–1.4) 3.8 (1.2–4.8)
Cmin (mg/liter) 11.6 (8.1–16.4) 3.5 (1.4–6.7)
t1/2 (h) 33.7 (24.7–74.5)
fAUC0–24 (mg · h/liter) 340.4 (263.5–523.7) 141.1 (68.2–267.0)
CLobs (liters/h) 0.5 (0.2–0.6)
Vss (liters) 20.4 (15.5–26.7)
a Pharmacokinetics after receiving a 400-mg dose.
b Cmax, maximum concentration observed; Tmax, time to reach Cmax; Cmin, minimum
concentration observed; CLobs, observed clearance; Vss, steady-state volume of
distribution.
FIG 1 Free median (interquartile range [error bars]) plasma and SC ISF flu-
conazole concentration-time profile in critically ill patients (pharmacokinetic
profile after receiving a 400-mg dose).
FIG 2 Comparison of the free area under the concentration-time curve from
0 to 24 h in plasma and subcutaneous interstitial fluid (means	 SD in plasma
and interstitial fluid were 393.3	 183.7 and 188.6	 146.6, respectively; P
0.006).
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while peripheral tissues still receive high blood flow as a result of
an increased cardiac workload and peripheral vasodilation,
whereas peripheral tissue hypoperfusion occurs during the later
stages of sepsis-related blood flow changes as a consequence of a
physiological effort to increase blood perfusion to vital organs
(27). Thus, using physiologically based PK simulations, Sasongko
et al. (24) have shown that fluconazole uptake into subcutaneous
ISF is dependent on blood flow to the subcutaneous tissue in
healthy volunteers. Moreover, significant sustained compromised
microcirculation in peripheral tissues was observed even after res-
toration of hemodynamics in sepsis patients (28, 29). Although
not statistically significant, our results suggest that use of vaso-
pressors, which result in peripheral vasoconstriction, may have an
influence on peripheral subcutaneous ISF penetration of flucona-
zole.
Mauric et al. (30) investigated fluconazole penetration into
skeletal muscle of rats with severe sepsis using microdialysis and
showed that free plasma fluconazole concentrations were super-
imposable with ISF concentrations in skeletal muscle. This finding
is in contrast to the observed penetration in our study. However,
the lipopolysaccharide-induced-sepsis rat model used by Mauric
et al. does not mimic all forms of inflammation observed in hu-
mans. Moreover, inflammation and sampling were limited in du-
ration to 6 h. It is possible that these differences—inflammatory
changes and a shorter inflammatory period—might explain the
incomplete distribution observed in our study.
Another important observation from this study was the heter-
ogeneous distribution of fluconazole into subcutaneous ISF (Fig.
2). This could be a result of differences in individual PK, as well as
the estimation of microdialysis probe recovery. It is generally rec-
ommended that the recovery rates be20% to minimize the vari-
ability associated with sample handling and analysis (31). The
mean in vivo recovery rate achieved in this study was 51.4%. Fur-
thermore, the mean fluconazole recovery rates achieved in the
current study were similar to those observed in healthy volunteers
(57%) (24) and in an in vivo study using a C. albicans-infected rat
model (50%) (32). Moreover, the observed in vivo recovery rate
variability in this study was similar to those attained in other stud-
ies (coefficient of variation, 31% versus 28 to 37%) (24, 32, 33).
Given the heterogeneous distribution and lack of readily identifi-
able clinical factors by which to recognize patients with reduced
distribution into ISF, it is evident that care should be taken when
adjusting doses based only on the concentration in plasma. In
plasma, as previously reported in a cohort of critically ill patients
(34), variability in the observed mean fluconazole fAUC0 –24 and
the Cmax and Cmin was higher than in surgical ICU patients (35)
and healthy volunteers (36). The underlying causes of this vari-
ability could be 2-fold—physiological changes that occur during
sepsis and patient-related factors, like weight and renal function.
Thus, a recent study (34) has shown that a standard one-dose-fits-
all approach, i.e., 400 mg without taking patient weight into ac-
count, would result in subtherapeutic fluconazole exposure in
critically ill patients. This variability in plasma exposures might
have also contributed to the incomplete distribution to ISF con-
centrations described above.
For fluconazole, an fAUC0 –24/MIC of100 has been shown to
be the predictive PK/PD target associated with clinical success
(25). A predictive PK/PD target in ISF has yet to be identified for
fluconazole. In general, the percentage of patients who attained
the PK/PD target decreased with increasing MICs in both plasma
and ISF. Considering that similar PK/PD targets may apply to ISF,
the percentage of patients attaining the PK/PD target was further
reduced in ISF (Fig. 3). However, a different PK/PD target for ISF
is highly possible. In patients infected with a susceptible Candida
sp. with a MIC below the breakpoint, the PK/PD target in plasma
would be attained in the majority of the patients with standard
doses. However, higher than standard doses would be required to
achieve similar targets in ISF. In patients infected with less-sus-
ceptible Candida spp., a lower exposure is highly likely to be a
problem in both plasma and ISF. If the MIC is high or unknown,
we recommend measuring fluconazole exposure or using higher
than standard doses to ensure that the exposure is adequate.
This study had some limitations. We did not measure the
unbound concentrations of fluconazole in plasma and used a
published protein binding value (12%) to estimate free plasma
fluconazole concentrations. Given the low protein binding of
fluconazole, the difference between the measured and esti-
mated fluconazole concentrations is unlikely to be significant
(37). We used the breakpoint MICs determined by EUCAST
and CLSI to estimate fluconazole PK/PD targets because of the
lack of actual MIC data for 10 of 12 patients. We measured the
fluconazole ISF concentration in the SC tissue of the upper arm
in this study. The PK in this peripheral site may be different
from that in other sites of infection, e.g., intra-abdominal or
epithelial lining fluid, for the above-mentioned reasons. Con-
sidering the ethical constraints for critically ill patients, we
chose to use SC tissue of the upper arm for this study. There-
fore, the results should interpreted cautiously, taking patient
status and the site of infection into consideration.
In summary, fluconazole was distributed incompletely from
plasma into subcutaneous ISF, with substantial variability be-
tween patients. In this cohort of critically ill patients, based on the
PK/PD target, the observed exposures obtained in plasma should
be sufficient to effectively treat susceptible Candida spp. Given the
heterogeneous distribution and lack of clinically identifiable fac-
tors by which to recognize patients with reduced distribution/
exposure, we recommend using higher than standard doses to
ensure that the exposure is adequate at the site of infection. De-
creased ISF penetration is one of the possible causes of treatment
failure, and further studies are warranted.
FIG 3 Percentages of patients who achieved the pharmacokinetic/pharmaco-
dynamic target of an fAUC0 –24/MIC of 100 in plasma and subcutaneous
interstitial fluid at breakpoints (n 12).
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